© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HCC
Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma
May 20, 2020
David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.
Cabozantinib May Be a Match for Regorafenib in Second line Advanced HCC
May 19, 2020
Based on data from a matching-adjusted indirect comparison study, cabozantinib the safety and efficacy of cabozantinib may be comparative to regorafenib in advanced hepatocellular carcinoma.
Personalized Treatment for Subtypes of HCC Is the Way of the Future
May 13, 2020
In an interview with Targeted Oncology, Yujin Hoshida, MD, PhD, discussed the next steps for improving upon the current understanding of hepatocellular carcinoma subtypes to improve responses and outcomes in patients.
Evaluating Current Challenges in Hepatocellular Carcinoma
May 07, 2020
Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.
FDA Grants Orphan Drug Designation to First Liver-Targeted Drug for HCC
May 06, 2020
"Having obtained an encouraging proof-of-concept for the liver-cancer directed effect of MIV-818 in phase Ia, we hope to get additional supportive data from the phase Ib study. We believe that MIV-818 has the potential to provide liver cancer patients with major therapeutic benefits."
Expert Reviews TKI Survival Data as Therapy for HCC
April 24, 2020
“If we’re going to get patients to second-line treatment, we have to get them to front line. That has to do with transitioning patients from locoregional therapy appropriately."
Studies Investigate Multiple Types of Therapies in HCC
April 16, 2020
Michael R. Charlton, MD, MBBS, discusses different types of therapy and trials in the hepatocellular carcinoma setting right now.
Sequencing Targeted Therapies and Immunotherapies in Hepatocellular Carcinoma
April 15, 2020
In an interview with Targeted Oncology, Lipika Goyal, MD, discussed the first- and second-line treatment options for patients with hepatocellular carcinoma and shared her thoughts on how these agents should be sequenced.
Immunotherapy Combinations Emerge as Likely Standard for Future HCC Management
April 14, 2020
The combination of PD-L1 and VEGF inhibition suggests promise for the treatment of unresectable hepatocellular carcinoma, according to findings of the phase III IMbrave150 study.
Real-Life Analysis of Nivolumab in Patients With HCC Align With Clinical Trial Data
April 07, 2020
In an interview with Targeted Oncology, Maria Reig, MD, PhD, discussed the results from the retrospective analysis of patients with hepatocellular carcinoma treated with nivolumab in the real-life setting in Spain.